Management Team

David B. CampDavid B. Camp, Co-Founder & Chairman of the Board

David Camp has extensive experience in the medical device field, with a particular focus on cardiovascular device markets. He has over 30 years’ experience in areas that include new product launch, sales and marketing, and direct distribution to cardiologists and cardiovascular surgeons for angioplasty and cardiac rhythm management devices. David has a successful track record for introducing new technology, developing successful distribution networks, and for establishing loyal surgeon user networks. His background includes Smith Kline, U.S. Surgical, American Edwards Corp. (AME), SciMed Life Systems (purchased by Boston Scientific), Medtronic, and St. Jude Medical. He was one of the original sales and marketing team responsible for the launch of the angiographic division of AME. He was also one of the original four sales representatives hired in 1987 to launch a new angioplasty technology nationwide for SciMed Life Systems. During his nine-year tenure with SciMed, his team was responsible for growing sales from zero to over $350 Million.

Robert G. Matheny, MDRobert G. Matheny, MD, Co-Founder, Director
Chief Scientific Officer & Chief Medical Officer

Dr. Robert Matheny is a cardiothoracic surgeon and distinguished pioneer of minimally invasive cardiac surgical procedures. Dr. Matheny did his undergraduate studies at the University of Oklahoma and Baylor University completing his MD at the University of Texas, performed his surgical residency at Texas A&M University, and completed his cardiothoracic fellowship at Ohio State University. He has been certified by the American Board of Surgery and the American Board of Thoracic Surgery.  Dr. Matheny has worked with a number of medical device companies as a consultant in off-pump heart surgery, atrial fibrillation, robotics, and ventricular support devices, including CardioThoracic Systems, Medtronic, Embolex, Amed Systems, Guidant, AFx and Corazon.  He has a long list of published articles and chapters and holds patents for many medical devices. Dr. Matheny is the Vice President of Research and Development as well as Scientific Advisory Board Director for CorMatrix and has worked with Extracellular Matrix materials for cardiovascular applications since 1993.  He is co-inventor on several of the Purdue ECM patents.

Andrew M. GreenAndrew M. Green, Chief Executive Officer & President

Andrew (Drew) Green joined the Company in July 2013 as the Vice President of Regulatory, Quality, and Clinical Development and became the Vice President of Operations in 2014, President in January 2016 and CEO in October 2016.  Drew has over 20 years of experience in in all aspects of medical devices.  Prior to CorMatrix, Drew was the VP of Regulatory and Clinical Affairs at Halscion, Inc., a private company developing an injectable hydrogel bioscaffold for dermal applications.

Drew’s previous experience also includes the position of Chief Executive Officer for Oncologix Tech, Inc., a publicly traded medical device company developing an interventional treatment for metastatic liver cancer, a principal in NeoMedica, LLC, a consulting group that specialized in medical device consulting for clients that included early stage ventures dealing with Class I, II, and III medical devices.  Prior to that, from 1996 until 2005, he was employed by the Novoste Corporation (a publicly traded medical device company) with a final position as a corporate officer with responsibility for Regulatory Affairs, Clinical Affairs, Quality Assurance and New Technology.  Drew started his career as a Scientific Reviewer/Biomedical Engineer for the FDA, where he was responsible for the review of scientific, technical, pre-clinical and clinical data submitted in support of the safety and effectiveness of both interventional and general cardiovascular devices.  Drew holds a BS degree in Biological Sciences and an MS degree in Bioengineering, both from Clemson University, where his research focused on characterization and use of materials in a biological environment.

 John C. Thomas, Jr.John C. Thomas, Jr., Chief Financial Officer & Secretary

John Thomas has served as the CFO and Secretary of the Company since inception.  Over the past 30 years, Mr. Thomas has served as the CFO of numerous startup companies and helped them raise initial capital from the initial financing up to their initial public offering. Some of these companies are still private and some have become public entities.  The companies in the health care industry that have gone public while Mr. Thomas was the CFO include CytRx Corporation (1986 – 1990), Medicis Pharmaceutical Corporation (1988 – 1991), EntreMed, Inc. (1991 – 1997), DARA BioSciences, Inc. (1998 – 2009), and MiMedx, Inc. (2006 – 2009).  Mr. Thomas is also the CFO of Motion Reality, Inc., a privately-held company with proprietary software that captures and analyzes motion data and has been since 1991.  Mr. Thomas is a board member of Motion Reality, Inc.,  QLT, Inc., a publicly traded biotechnology company, NantKwest, Inc., a publicly traded immunotherapy company focused on cancer, and Medovex, Inc., a publicly traded biotechnology company.  Mr. Thomas is a graduate of the McIntire School of Commerce of the University of Virginia and is a certified public accountant.

Patrick FergusonPatrick Ferguson, Executive Vice President of Sales & Marketing

Patrick Ferguson joined the Company in 2012 as an Area Sales Director and in January of 2016 became the Executive Vice President of Sales and Marketing.  Patrick brings over 18 years of leadership and sales experience in delivering strategic vision, culture development, and sales excellence to CorMatrix.  He has played an integral part in the launch of the Vascular and Electrophysiology product lines for CorMatrix based on his prior experience in those areas. Prior to joining CorMatrix, Patrick spent 12 years with Medtronic as a District Manager and Senior Sales Rep in their CRM division.  Previous to this, he was with St Jude Medical in sales for their CRM division.  Mr. Ferguson received his Bachelor of Science degree from the University of Florida.

Jason Aryeh – Director

Jason M. Aryeh has served as a Director since 2010.  Mr. Aryeh is the founder and managing general partner of JALAA Equities, LP, a private hedge fund focused on the biotechnology and specialty pharmaceutical sector, and has served in such capacity since 1997. Since 2012, Mr. Aryeh also serves as Chairman of the Board of QLT, Inc., a publicly traded biotechnology company. In addition, he is a director of Ligand Pharmaceuticals, a public biotechnology company, and Aralex Pharmaceuticals, a public specialty pharmaceutical company, as well as of the Cystic Fibrosis Foundation’s Therapeutics Board (CFFT).  He previously served as a board member of Nabi Biopharmaceuticals and Myrexis, Inc. both public biotechnology companies.  Mr. Aryeh received his B.A in economics, with honors, from Colgate University and is a member of the Omnicron Delta Epsilon Honor Society in economics.

Blane Crutchfield – Director

Blane has served as a member of the Company’s Board of Directors since inception.  He is a partner at Hand Arendall LLC, a regional law firm headquartered in Alabama. Blane has been in private practice for 29 years and has served as counsel to a number of small and medium sized companies.  Blane and his firm have represented the Company since its inception.

G. Ruffner Page, Jr.  – Director

Ruffner Page has served President of McWane, Inc. since 1999. Mr. Page joined the company in 1993 working in the area of mergers and acquisitions. Prior to coming to McWane, he held management positions at National Bank of Commerce from 1989 to 1993, the Remington Fund from 1986 to 1989, and Bankers Trust Company in New York and Atlanta.

Mr. Page currently serves on the Board of Directors of McWane, Inc., Southern Research Institute and the National Bank of Commerce. He is a member of the Downtown Rotary, Leadership Birmingham and Leadership Alabama.  He serves on the Boards of the Birmingham Airport Authority, the Birmingham Education Foundation, the Community Foundation of Greater Birmingham, the Birmingham Museum of Art and the Alabama Symphony Orchestra.

Mr. Page graduated from Vanderbilt University in Nashville, Tennessee with a B.A. in Philosophy and Psychology with a minor in Economics. He is also a 1986 graduate of the University of Virginia, Darden School of Business in Charlottesville, Virginia.